Abstract
Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an alio- or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.
| Original language | English |
|---|---|
| Pages (from-to) | 125-132 |
| Number of pages | 8 |
| Journal | Cell Transplantation |
| Volume | 16 |
| Issue number | 2 |
| Publication status | Published - 2007 |
Fingerprint
Keywords
- Encapsulation
- GDNF
- Parkinson's disease
- Stem cell
- Tet-off
- VEGF
ASJC Scopus subject areas
- Cell Biology
- Transplantation
Cite this
Intracerebral transplantation of genetically engineered cells for Parkinson's disease : Toward clinical application. / Yasuhara, Takao; Date, Isao.
In: Cell Transplantation, Vol. 16, No. 2, 2007, p. 125-132.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intracerebral transplantation of genetically engineered cells for Parkinson's disease
T2 - Toward clinical application
AU - Yasuhara, Takao
AU - Date, Isao
PY - 2007
Y1 - 2007
N2 - Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an alio- or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.
AB - Over the last decade, molecular biology has progressively developed, leading to new technology with subsequent clinical application for various cerebral diseases including Parkinson's disease (PD), one of the most investigated neurodegenerative disorders. The therapy for PD is mainly composed of medication, including drug replacement therapy, surgical treatment, and cell transplantation. Cell therapy for PD has been explored by using fetal nigral cells as an alio- or xenograft, autologous sympathetic ganglion, adrenal medulla, and carotid body in clinical settings. In addition, neurotrophic factors, including glial cell line-derived neurotrophic factor (GDNF), have a strong potency to rescue degenerating dopaminergic cells. Protein and/or gene therapy also might be a therapeutic option for PD. In this review, genetically engineered cell transplantation for animal models of PD, including catecholamine/neurotrophic factor-secreting cell transplantation with or without encapsulation, as performed in our laboratories, and their potential future as clinical applications are described with recent clinical studies in this field.
KW - Encapsulation
KW - GDNF
KW - Parkinson's disease
KW - Stem cell
KW - Tet-off
KW - VEGF
UR - http://www.scopus.com/inward/record.url?scp=34247579230&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247579230&partnerID=8YFLogxK
M3 - Article
C2 - 17474294
AN - SCOPUS:34247579230
VL - 16
SP - 125
EP - 132
JO - Cell Transplantation
JF - Cell Transplantation
SN - 0963-6897
IS - 2
ER -